Digital representation of the globe.

In the wake of the coronavirus pandemic, pressure has come from regulatory agencies, the public, patients, advocates, pharmaceutical industry watchdogs, and investors for increased clinical transparency. This white paper takes a look at a broad spectrum of global disclosure regulations, whether penalties exist for noncompliance and, if so, whether they are being enforced.

Failure to register and fully report clinical trials harms patients, wastes taxpayers’ money, and slows down the development of new treatments, vaccines and cures.
Till Bruckner

Related resources

Hands with a digital icon for security hovering above them.
SEP 01, 2023
White paper
Regulatory & Compliance

Clinical Trial Disclosure Compliance a Moving Target Due to Ever-changing Global Regulations

Gain insights on key factors driving disclosure rule updates and ways to minimize noncompliance risks.

hidden costs of clinical trial disclosure
OCT 06, 2023
Regulatory & Compliance

9 Hidden Costs of Trial Disclosure

From system implementation to protocol registration and process assessment, hidden costs lurk at every step of the clinical trial disclosure process.

Biopharma professional on laptop browsing Pink Sheet for global policy and regulatory insights.
MAY 01, 2022
Regulatory & Compliance

Your Keys to Understanding EU Transparency

A collection of Pink Sheet articles covering evolving EU regulations on clinical trial disclosure and transparency